Sat, Jan 21, 2017 - Page 8 News List

Dealing with conflicts of interest

By Wong Yu-feng 翁裕峰

Academia Sinica has drawn up and promulgated Academia Sinica Principles of Avoiding and Managing Conflicts of Interests in Technology Transfers.

In accordance with the Act on Recusal of Public Servants Due to Conflict of Interest (公職人員利益衝突迴避法), Article 3 of the 2006 draft of the Academia Sinica principles clearly defines “[r]elatives of the public servant by the second degree of kinship” as “related persons of a public servant” and stipulates that any conflict of interest with such people must be disclosed.

Academia Sinica’s human resources department also issued an article that quotes the Civil Code, saying that children of civil servants also belong to this group and must submit a conflict of interest report.

In August, 2012, the institute’s conflict of interest regulation was passed, and in January 2013, a disclosure form was announced, but children of civil servants were listed as not required to submit such a form.

This is in blatant violation of the original draft and interpretation of “relatives ... of the second degree of kinship” by the human resources department.

In March and April 2012, an investigation at OBI Pharma’s parent company in the US found that its Taiwanese daughter company had inappropriately given US$300,000 to a research lab in July 2011, and that staff at the lab were connected to a gift of OBI Pharma shares.

In September that year, OBI Pharma tried to give its chairman, Michael Chang (張念慈), 1.5 million technology shares.

The company’s US parent launched the investigation because it felt that these two events were in violation of the US’ Foreign Corrupt Practices Act and other related legislation.

While prosecutors brought charges against Wong for having received shares about a year after these events, coincidentally, the way the shares were obtained and the number of shares were identical to what the US parent company had found in its investigation: One-and-a-half million tech shares in OBI Pharma, and 3 million shares in OBI Pharma received in 2012.

One of the reasons that the system has become distorted is because the enabling act provides no concrete regulations. A second reason is that there are no requirements that managers at an individual institution disclose conflicts of interest to their superiors. A third reason is that the shares had been obtained after the draft regulations had been issued by Academia Sinica, but before the disclosure form had been created.

A national system for the disclosure of conflicts of interest needs to be stipulated in the Fundamental Science and Technology Act as soon as possible to enable researchers to have a clear understanding of which is more important of research interests and the financial interests resulting from technological transfers.

If this is not done and individual research institutions continue to be allowed to set their own regulations, the continuing research cooperation between Academia Sinica and OBI Pharma into oligosaccharides implies a risk that yet another top-level biotech researcher at Academia Sinica will go on to repeat the same mistake.

Wong Yu-feng is an assistant researcher at National Cheng Kung University’s Center for Humanities and Social Sciences.

Translated by Tu Yu-an and Perry Svensson

This story has been viewed 4445 times.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top